Advisors Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Advisors Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$566K	Buy	4,940 +62	+1%	+$5.33K	0.01%	960
2026 Q1	$406K	Sell	4,878 -63	-1%	-$4.99K	0.01%	1011
2025 Q4	$384K	Sell	4,941 -2	-0%	-$135	0.01%	1015
2025 Q3	$280K	Sell	4,943 -19	-0.4%	-$857	﹤0.01%	1076
2025 Q2	$217K	Buy	4,962 +3	+0.1%	+$103	﹤0.01%	1109
2025 Q1	$136K	Buy	4,959 +2,230	+82%	+$81.3K	﹤0.01%	1149
2024 Q4	$110K	Buy	+2,729	New	+$123K	﹤0.01%	1209
2024 Q1	–	Sell	-6,893	Closed	-$175K	–	1422
2023 Q4	$175K	Sell	6,893 -155	-2%	-$2.77K	﹤0.01%	1130
2023 Q3	$98K	Sell	7,048 -78	-1%	-$1.57K	﹤0.01%	1195
2023 Q2	$164K	Sell	7,126 -550	-7%	-$15.8K	﹤0.01%	1149
2023 Q1	$227K	Buy	7,676 +5,349	+230%	+$173K	﹤0.01%	1091
2022 Q4	$58.1K	Buy	+2,327	New	+$62K	﹤0.01%	1326

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Advisors Asset Management's KYMR Position: Q2 2026 in Review

Advisors Asset Management increased its Kymera Therapeutics (KYMR) stake by 1.3% in Q2 2026, buying an estimated $5.33K and bringing the position to 4,940 shares worth $566K. The position accounts for 0.01% of the portfolio, ranked #960.

Advisors Asset Management first reported a position in KYMR in Q4 2022 and has held it in 12 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Advisors Asset Management held 4,940 shares of Kymera Therapeutics worth $566K as of Q2 2026.
Advisors Asset Management bought 62 Kymera Therapeutics shares in Q2 2026, an estimated $5.33K.
Kymera Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #960 holding.
Advisors Asset Management first reported a position in Kymera Therapeutics in Q4 2022 and has held it in 12 quarters since.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.